GENOME EDITINGFOR A BETTER LIFE

> Our Pipeline> Ex Vivo Therapies

ET-01

  • Therapeutic Approach

    Using gene-editing technology to edit BCL11A erythroid enhancer in hematopoietic stem cells (HSC), ET-01 is an autologous cell therapy being developed to increase the fetal hemoglobin level in red blood cells for severe β-thalassemia patients.

  • Poster Presentation at the 61st ASH Annual Meeting

    EdiGene presented the manufacturing scale-up and preclincial development data of ET-01 for the β-thalassemia gene editing treatment at the 61st ASH annual meeting in 2019.

ET-02

  • Therapeutic Approach


    Edit immuno-rejection molecules in  T cells from healthy donors, leveraging partner’s proprietary CAR-T to create best-in-class U CART process and U CAR-T product.